Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064976
Filing Date
2025-05-07
Accepted
2025-05-07 07:01:36
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apls-20250331.htm   iXBRL 10-Q 1864368
2 EX-10.1 apls-ex10_1.htm EX-10.1 78043
3 EX-31.1 apls-ex31_1.htm EX-31.1 17335
4 EX-31.2 apls-ex31_2.htm EX-31.2 17564
5 EX-32.1 apls-ex32_1.htm EX-32.1 9984
6 EX-32.2 apls-ex32_2.htm EX-32.2 10094
7 GRAPHIC img11184494_0.jpg GRAPHIC 13537
8 GRAPHIC img11184494_1.jpg GRAPHIC 7179
  Complete submission text file 0000950170-25-064976.txt   8109986

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apls-20250331.xsd EX-101.SCH 1127091
75 EXTRACTED XBRL INSTANCE DOCUMENT apls-20250331_htm.xml XML 1389600
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 25919221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)